Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
Synchronous lung metastasis occurs in less than 1% of patients with renal masses less than 4 cm in diameter, so chest imaging in these cases may be unwarranted, according to investigators.
Compared with men, women had significant 18% lower odds of undertreatment and 27% higher odds of overtreatment of kidney cancer, according to a study.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Systematic review and meta-analysis assessed the impact of delayed surgical intervention on localized and metastatic renal cell carcinoma.
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.